No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group

Cancer. 1993 Mar 1;71(5):1741-5. doi: 10.1002/1097-0142(19930301)71:5<1741::aid-cncr2820710507>;2-q.


Background: Experimental, and more recently, clinical data have suggested the influence of hemostasis in the spread of malignant disease.

Methods: To complete research in this type of coagulation and cancer, a multicentric randomized clinical trial was performed, including 303 patients with small cell lung cancer (SCLC), treated by the addition of aspirin at 1 g/day (a dosage at which aspirin is considered to be a platelet aggregation inhibitor) to combined chemotherapy.

Results: Survival was not increased in the aspirin-treated group (P = 0.90). The analysis according to the extent of disease (limited or extensive disease) did not modify that conclusion.

Conclusions: This result does not confirm the hypothesis that, in SCLC, aspirin (a platelet aggregation inhibitor) reduces metastasis formation and local tumor thrombogenesis.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Aspirin / pharmacology
  • Aspirin / therapeutic use*
  • Carcinoma, Small Cell / drug therapy*
  • Carcinoma, Small Cell / mortality
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Lomustine / administration & dosage
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Male
  • Melphalan
  • Middle Aged
  • Platelet Aggregation / drug effects*
  • Prednisone
  • Survival Rate


  • Etoposide
  • Lomustine
  • Doxorubicin
  • Cyclophosphamide
  • Melphalan
  • Aspirin
  • Prednisone

Supplementary concepts

  • CAVP protocol
  • CCAVP16 protocol